News & Updates

Show Multimedia Only

$Explore the evidence for carvedilol in heart failure with reduced ejection fraction (HFrEF), with a focus on its demonstrated$

Explore the evidence for carvedilol in heart failure with reduced ejection fraction (HFrEF), with a focus on its demonstrated benefits in reducing mortality, hospitalization, and disease-related morbidity.

14 Sep 2026

Heart failure with reduced ejection fraction (HFrEF) remains a major cause of morbidity and mortality, with recurrent hospitalizations often marking a challenging phase in the patient journey. For patients, being discharged is not the end of their treatment journey. While discharge from the hospital represents an important milestone, long-term management is essential to reduce the risk of clinical deterioration and improve survival.¹Carvedilol, a beta-blocker recommended as part of guideline-directed treatment for heart failure. Guideline-directed medical therapy (GDMT) refers to the combination of evidence-based medicine recommended to improve outcomes for patients with HFrEF. Current treatment generally centers on four key pillars: an angiotensin receptor–neprilysin inhibitor (ARNi), a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and a beta-blocker such as carvedilol. Together, these therapies work through different pathways to help reduce symptoms, slow disease progression, lower the risk of hospitalization, and improve survival.

Explore the evidence for carvedilol in heart failure with reduced ejection fraction (HFrEF), with a focus on its demonstrated benefits in reducing mortality, hospitalization, and disease-related morbidity.

14 Sep 2026

Healthy seniors get cardioprotective benefit with statins

14 Sep 2026 by

Use of statins in the primary prevention setting yields a substantial reduction in the risk of major cardiovascular events in community-dwelling adults at least 70 years of age, as shown in the STAREE trial.

Healthy seniors get cardioprotective benefit with statins

14 Sep 2026

Compound exposure to heat wave, SFAP elevates risk of CV deaths

14 Sep 2026

Individuals with multiple exposure to extreme heat and substantial fire-sourced air pollution (SFAP) are at greater risk of cardiovascular mortality than those with single exposures, a study has found.

Compound exposure to heat wave, SFAP elevates risk of CV deaths

14 Sep 2026

SGLT-2 inhibitors may avert portal hypertensive complications, death in cirrhosis patients

14 Sep 2026

Use of SGLT-2 inhibitors among patients with cirrhosis helps prevent portal hypertensive complications and improve survival, suggests a study.

SGLT-2 inhibitors may avert portal hypertensive complications, death in cirrhosis patients

14 Sep 2026

Aficamten retains upper hand over metoprolol for oHCM in subanalysis

14 Sep 2026 by

Results from a subanalysis of the MAPLE-HCM* trial presented at ESC 2026 continue to support the superiority of aficamten over metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) irrespective of beta-blocker (BB) use at screening and prior standard-of-care (SoC) status.

Aficamten retains upper hand over metoprolol for oHCM in subanalysis

14 Sep 2026

Novel oral relaxin receptor agonist shows promise in chronic heart failure

12 Sep 2026 by

In patients with chronic heart failure (HF), the addition of the oral relaxin family peptide receptor 1 (RXFP1) agonist AZD5462 to guideline-directed medical therapies (GDMTs) may help improve cardiac remodelling and haemodynamics across a wide range of left ventricular ejection fraction (LVEF), according to the phase IIb LUMINARA study.

Novel oral relaxin receptor agonist shows promise in chronic heart failure

12 Sep 2026

Elevated serum ApoE ups incident CVD risk

12 Sep 2026 by

Higher circulating apolipoprotein A (ApoE) concentrations appear to increase the risk for incidence major adverse cardiovascular events (MACE), ischaemic heart disease (IHD), and heart failure, suggests a study.

Elevated serum ApoE ups incident CVD risk

12 Sep 2026

Cumulative BP exposure a better predictor of CV outcomes, mortality

11 Sep 2026

Cumulative blood pressure (BP) exposure over the previous 10 years results in improved prediction of incident cardiovascular events and mortality beyond that derived from a single value, according to a study.

Cumulative BP exposure a better predictor of CV outcomes, mortality

11 Sep 2026

Uromodulin levels do not predict hypertension

11 Sep 2026 by

Uromodulin, as a protein and genetic biomarker, is not a reliable predictor of hypertension or hypertension-related outcomes, reveals a study. However, it may have potential use in the prediction of other cardiovascular outcomes.

Uromodulin levels do not predict hypertension

11 Sep 2026

Inclisiran outdoes BPA for LDL-C lowering in high CV risk patients

11 Sep 2026 by

In the phase IV VICTORION-Challenge trial, inclisiran outperforms bempedoic acid (BPA) for lowering LDL-C in individuals with high and very high cardiovascular (CV) risk.

Inclisiran outdoes BPA for LDL-C lowering in high CV risk patients

11 Sep 2026

News & Updates

Showing Cardiology articles

Showing

Specialty:

Explore the evidence for carvedilol in heart failure with reduced ejection fraction (HFrEF), with a focus on its demonstrated benefits in reducing mortality, hospitalization, and disease-related morbidity.

Explore the evidence for carvedilol in heart failure with reduced ejection fraction (HFrEF), with a focus on its demonstrated benefits in reducing mortality, hospitalization, and disease-related morbidity.

Healthy seniors get cardioprotective benefit with statins

Healthy seniors get cardioprotective benefit with statins

Compound exposure to heat wave, SFAP elevates risk of CV deaths

Compound exposure to heat wave, SFAP elevates risk of CV deaths

SGLT-2 inhibitors may avert portal hypertensive complications, death in cirrhosis patients

SGLT-2 inhibitors may avert portal hypertensive complications, death in cirrhosis patients

Aficamten retains upper hand over metoprolol for oHCM in subanalysis

Aficamten retains upper hand over metoprolol for oHCM in subanalysis

Novel oral relaxin receptor agonist shows promise in chronic heart failure

Novel oral relaxin receptor agonist shows promise in chronic heart failure

Elevated serum ApoE ups incident CVD risk

Elevated serum ApoE ups incident CVD risk

Cumulative BP exposure a better predictor of CV outcomes, mortality

Cumulative BP exposure a better predictor of CV outcomes, mortality

Uromodulin levels do not predict hypertension

Uromodulin levels do not predict hypertension

Inclisiran outdoes BPA for LDL-C lowering in high CV risk patients

Inclisiran outdoes BPA for LDL-C lowering in high CV risk patients